The Evidence on E-cigarettes: Evaluating What We Have and Identifying What We Need

Similar documents
FDLI Tobacco Products Regulation and Policy Conference Joe Murillo Vice President, Regulatory Affairs October 27, 2017

Modeling of E-cigarette Use. David Levy, PhD Georgetown University

How to Regulate E-Cigarettes? Are we asking the right questions?

Should FDA try to move smokers to e-cigarettes or other less harmful tobacco-nicotine products and, if so, how?

Smoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017

Use of e-cigarettes (vapourisers) among adults in Great Britain

FDA s Nicotine Steering Committee should develop policies, regulations, and procedures that promote cessation and increase the use of proven therapies

American Vaping Association

ELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE?

The Latest on Vaping Among U.S. Teens

Electronic Nicotine Delivery Systems: Patterns of Use and Disparities

RADM Patrick O Carroll, MD, MPH Senior Advisor, Assistant Secretary for Health, US DHSS

TOBACCO PLAYBOOK DÉJÀ VU: E-CIGARETTES

The Epidemiology of Poly Substance Use Among Youth and Adults

Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re

Tobacco Data, Prevention Spending, and the Toll of Tobacco Use in North Carolina

Smoking Harm Reduction: If Not Now When?

The gateway theory. Pr Jean-François ETTER PhD (political science) E-cigarette Summit London, November 17, Competing interests: none

Policy Trends and ENDS on College Campuses

Electronic Cigarettes: What They Are, How They re Marketed, & How We Can Protect Our Youth

E-cigarettes in Europe : a consumer led revolution

Reframing the E-cigarette Debate To Address Genuine Harm Reduction

TREATMENT OF TOBACCO USE DISORDERS E-CIGS & APPS

The English experience in a European regulatory context. E-cigarette summit Washington DC 1 st May 2018 Deborah Arnott Chief Executive ASH (UK)

Project ECHO Importance of Treating Tobacco Use In People With Behavioral Health Disorders Jan Blalock, Ph.D.

Non-Industry Voices on Tobacco Harm Reduction and Vaping Products

Improving E-Cigarette Research through Measurement and Design ANDREA VILLANTI, PHD MPH E-CIGARETTE SUMMIT MAY 8, 2017

Modeling the Population Health Effects of Camel Snus with Reduced Risk Information

E.cigarettes. An alternative to a uniquely deadly product that kills one in two of its regular users? Paul Lambert Public Health, Leeds City Council

Prevent disease Protect from injury Promote healthy lifestyles

Tobacco Control: Big Fast Benefits. Stanton A. Glantz, PhD Professor of Medicine University of California San Francisco

How to think AND feel about nicotine and the people who use it

abstract ARTICLE NIH BACKGROUND: Adolescent e-cigarette use has increased rapidly in recent years, but it is unclear

Welcome to the wild, wild west.

Kent, OH May 22, 2018 TOBACCO 21

The New Zealand experience with electronic cigarettes

Clearing The Air about: Gretchen Hagenbuch, M.Ed. SAP Coordinator Philadelphia Region

Potential Consequences of E-Cigarette Use: Is Youth Health Going Up in Smoke? October 11, 2016

E-cigarettes: Evidence, perceptions and misconceptions. Martin Dockrell, Tobacco Control Programme Lead

Effectiveness of electronic cigarettes for smoking substitution

Texas Bill to Regulate Vapor Products. Over the past few years, electronic cigarettes, also commonly referred to as e-cigarettes

Disentangling the gateway hypothesis: does e-cigarette use cause subsequent smoking in adolescents?

Tobacco Use in Adolescents

West Milford Township Public Schools. Substance Abuse Policy and Regulation Review. and Vape Education for Parents. April 26, 2018

Predicting the population health effects of changing tobacco exposures: Statistical models for regulatory compliance

Electronic cigarettes disruptive innovation, public health potential and regulatory challenge

Electronic Cigarettes: What we know so far

Nicotine Reduction: Harm Reduction not Prohibition

Discussion points on Bill S-5

Horace Greeley High School Parent Presentation Vaping, E-cigs and the Health of Our Youth. Richard Stumacher, MD, FCCP January 18, 2018

E-cigarettes surpass tobacco cigarettes among teens

Trends in electronic cigarette use in England

Preventing Youth Electronic Cigarette Use: Partnering with Schools

Wayne Hall and Coral Gartner University of Queensland

E-Cigarettes: Current Perspective

Phil Mohler, M.D Crossroads Blvd P.O. Box Grand Junction, CO July 2016

Can E-cigarettes Help Curb the Smoking Epidemic in China?

e-cigarette impact on Public Health

Effectiveness of electronic cigarettes for smoking substitution

4/7/2015. Controversies in Cardiovascular Prevention. What is Preventive Cardiology? How Does the Population Get Routine Health Information?

Using evidence to negotiate new policies on harm reduction

Electronic Cigarettes, Nicotine and Policy Implications

MDQuit Best Practices Conference January 26, Presented by William C. Tilburg Deputy Director

Electronic Nicotine Delivery System (ENDS) Surveillance in the United States

Electronic cigarettes: A new era for tobacco harm reduction Adapted for SW Specialist Nurses for Children in Care meeting 17 January 2017

Smoking Cessation: A readily modifiable risk factor

Proposed Kitsap Public Health District Vapor Products Ordinance Responsiveness Record

Public Health England s Independent Expert E-Cigarettes Evidence Review

12 Vaping Stats & Trends for the Informed E-Cig Retailer

PROJECT NEWS. Youth and Young Adult Vaping in Canada. Background. Methods. Key Findings

Electronic Cigarette Use and Respiratory Symptoms in Chinese Adolescents in Hong Kong. Title. Wang, MP; Ho, DSY; Leung, LT; Lam, TH

Electronic Cigarettes and the Medical Society

Is Vaping a Valid Strategy for Smoking Cessation? Myths and Facts Jaspreet S. Brar. MD, PhD Community Care Behavioral Health Organization

Survey of U.S. Adult Cigarette Smokers

The Voice of Local Public Health in New York State. May 12, 2014

Final Frequencies (n=1,000) NATIONAL HEALTH SURVEY The Mellman Group & Public Opinion Strategies April 11, 2017

Tobacco Dependence: Assessment and Treatment. Douglas Arenberg

Menthol cigarettes are a public health problem

Are Electronic Vapor Products New Gateway Drugs to Other Substance Abuse among High Schoolers?

Key findings from a national survey of 1,000 registered voters, conducted February 2-5, Project # 15054

PRO/CON: Are federal regulations needed for e-cigarettes?

Use of electronic cigarettes (vapourisers) among adults in Great Britain

Electronic Nicotine Delivery Systems

National Conference of State Legislatures Legislative Summit: Clearing the Air About E-Cigarettes

ELECTRONIC CIGARETTES AND YOUTH

REGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING. Ron Borland PhD

risk of cigarette initiation among adolescents in the transition to adulthood when the sale of cigarettes becomes legal.

Centers for Disease Control and Prevention s Office on Smoking and Health

Introduction. Principles

/msdcenter. msdcenter. Tomorrow in Austin and via Livestream: msdcenter.org

Fumo, riduzione del danno e rischio oncologico

Current use of an electronic vapor product (such as an e-cigarette), state and regional comparison

ESPs are battery-operated devices that contain cartridges filled with liquid chemicals. The chemicals turn into a vapour that the user inhales (this

Melodie Tilson, Director of Policy

E-cigarettes Evidence Brief: March 2018

E-Cigarettes: A Game Changer. Dr. Blake Brown Hugh C. Kiger Professor Agriculture and Resource Economics College of Agriculture & Life Sciences

Improving the quality of research on e- cigarettes

Alcohol & Drug Services of Gallatin County adsgc.org March The Adolescent Resource Center (ARC)

Safety/risk assessment of electronic cigarettes

Transcription:

The Evidence on E-cigarettes: Evaluating What We Have and Identifying What We Need Ken Warner University of Michigan School of Public Health U.S. E-cigarette Summit, Washington, DC, May 8, 2017

Conflicts Disclosures I have no professional conflicts of interest. I am conflicted about being in this meeting on a beautiful day for golfing in northern Michigan. Funding sources I have no visible means of support for this presentation or anything else I do.

Areas of difference between e-cigarette enthusiasts & skeptics Issue Enthusiasts Skeptics Degree of risk reduction >95% Unknown; likely much <95% Primary articulated concern Maximizing adults quitting smoking Minimizing risks to kids Nature/magnitude of risks to kids Minimal; e-cigarettes may substitute for smoking Feared substantial: gateway to smoking; renormalization; effects on developing brain Impact on adult quitting Potential to help millions May reduce quitting Precautionary principle Smoking toll is an emergency; requires support of novel products Long-term nicotine addiction Acceptable if eliminates smoking Not acceptable Cigarette and e-cig companies Open to working with them Not to be trusted First do no harm ; need to first prove (relative) safety & effectiveness Free market Strongly support Worry about Wild West Scientific studies Support/discredit Support/discredit Product regulation Information dissemination Policies, e.g., vaping where smoking prohibited; flavors; taxation Favor limited regulation that won t disrupt innovation Emphasize harm reduction potential for adult smokers Oppose location restrictions; support flavors (to assist in adult quitting); no/low tax Support strong regulation to ensure safety/effectiveness Emphasize risks for kids and risks of dual use for adults Support location restrictions; oppose flavors (to reduce attractiveness to kids); tax

Areas of difference between e-cigarette enthusiasts & skeptics Issue Enthusiasts Skeptics Degree of risk reduction >95% Unknown; likely much <95% Primary articulated concern Maximizing adults quitting smoking Minimizing risks to kids Nature/magnitude of risks to kids Minimal; e-cigarettes may substitute for smoking Feared substantial: gateway to smoking; renormalization; effects on developing brain Impact on adult quitting Potential to help millions May reduce quitting Precautionary principle Smoking toll is an emergency; requires support of novel products Long-term nicotine addiction Acceptable if eliminates smoking Not acceptable Cigarette and e-cig companies Open to working with them Not to be trusted First do no harm ; need to first prove (relative) safety & effectiveness Free market Strongly support Worry about Wild West Scientific studies Support/discredit Support/discredit Product regulation Information dissemination Policies, e.g., vaping where smoking prohibited; flavors; taxation Favor limited regulation that won t disrupt innovation Emphasize harm reduction potential for adult smokers Oppose location restrictions; support flavors (to assist in adult quitting); no/low tax Support strong regulation to ensure safety/effectiveness Emphasize risks for kids and risks of dual use for adults Support location restrictions; oppose flavors (to reduce attractiveness to kids); tax

Prospective studies of use of e-cigarettes and subsequent smoking Huh and Leventhal, Am J Prev Med, 2016 Barrington-Trimis et al., Pediatrics, 2016 Leventhal et al., JAMA, 2015 Leventhal et al., JAMA, 2016 Miech et al., Tob Control, 2017 Primack et al., JAMA Ped, 2015 Wills et al., Tob Control, 2016 Wills et al., Psychol Addict Behav, 2016 Wills et al., Tob Control, 2017 Spindle et al., Addictive Behaviors, 2017

Limitations of prospective studies 1. How control adequately for fact that vapers are different from non-vapers? 2. Control for use of other psychoactive substances 3. What happens when controls do capture major differences between vapers and non-vapers? 4. Extent of cigarette use at follow-up 5. Small size of studies

30-day product use by US high school students, NYTS, 2011-2015 Singh et al., MMWR, 2016

The LAST TIME you used an electronic vaporizer such as an e-cigarette, what was in the mist you inhaled? 12 th graders in MTF, by smoking status, 2015 (%) Smoking E-cig mist Never Once/twice Occasionally Regularly in the past Regularly at present Nicotine 11.3 17.9 34.0 38.5 63.7 Marijuana or hash oil 3.4 6.4 9.4 11.4 5.9 Just flavoring 78.4 68.2 48.6 47.6 25.5 Other 0.4 1.3 0.6 0 1.5 Don't know 6.5 6.2 7.3 2.5 3.4

The LAST TIME you used an electronic vaporizer such as an e-cigarette, what was in the mist you inhaled? 12 th graders in MTF, by smoking status, 2015 (%) Smoking E-cig mist Never Once/twice Occasionally Regularly in the past Regularly at present Nicotine 11.3 17.9 34.0 38.5 63.7 Marijuana or hash oil 3.4 6.4 9.4 11.4 5.9 Just flavoring 78.4 68.2 48.6 47.6 25.5 Other 0.4 1.3 0.6 0 1.5 Don't know 6.5 6.2 7.3 2.5 3.4

12 th graders e-cigarette use in past 30 days by ever-smoking status, 2014 Ever-smoking status Used e-cigarettes (%) Never 6.5 Once or twice 25.8 Occasionally, not regularly 47.8 Regularly in past 46.8 Regularly now 57.3 Warner, AJPM, 2016 (MTF data)

Estimated increased number of additional long-term quitters associated with e-cigarette use in England 16,000-22,000 by one indirect estimation method; 22,000-28,000 by another (in 2014) West et al., Addiction, 2016 18,000 using ARIMAX modelling approach (in 2015) Beard et al., BMJ, 2016

Assumptions for simulation 1. E-cigarette use leads never-smoking kids to try smoking 2. Assume a very high estimate of how much Results in 4.2% increase in 18 year-old smokers Applies to every cohort of 18 year-olds through 2050! 3. Assume e-cigarettes increase net smoking cessation rate by 5% 4. All smokers subject to age-specific quit probability (total 4.2%) 5. All smokers, former smokers, and never smokers subject to age- and smoking-status-specific death rates 6. Track numbers of smokers and life-years lost for (youthful) vaping-induced smokers and gained for (adult) vaping-induced quitters through 2050

Cumulative life-years saved or lost by scenario, 2014-2050 Year Scenario 1: Initiation rate 4.2% Change in life-years Scenario 2: Quit rate 5% Scenario 3: Both initiation and quit rates 2014 0 1,649 1,649 2020 0 39,157 39,157 2030 293 269,364 269,074 2040 14,980 741,517 726,727 2050 88,413 1,332,905 1,245,639

Models examining impacts of e-cigarettes or generic reduced-risk products Bachand and Sulsky, Regulatory Toxicology and Pharmacology, 2013 Kalkhoran and Glantz, JAMA Int Med, 2015 Vugrin et al., PLOS ONE, 2015 Levy et al., NTR, 2016 Cherng et al., Epid, 2016

Thanks